id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1993-P-0037-0031,FDA,FDA-1993-P-0037,"Petition Denial from FDA CDER to Wiley, Rein & Fielding",Other,Denial,2014-03-07T05:00:00Z,2014,3,2014-03-07T05:00:00Z,,2025-01-28T16:15:12Z,,0,0,09000064804fbef6
FDA-1993-P-0037-0030,FDA,FDA-1993-P-0037,"Tab A 1- 2 - Mylan Pharmaceuticals, Inc. - [Wiley, Rein & Fielding - Petition for Stay]",Other,PSA-Petition for Stay,2010-05-28T04:00:00Z,2010,5,2010-05-28T04:00:00Z,,2010-10-29T01:01:31Z,,0,0,09000064804fbec5
FDA-1993-P-0037-0024,FDA,FDA-1993-P-0037,"Tab D - Letter from Wiley, Rein & Fielding to FDA DMB re: Petition for Stay",Other,Background Material,2010-05-27T04:00:00Z,2010,5,2010-05-27T04:00:00Z,,2025-09-19T20:05:53Z,,0,0,09000064804fbea5
FDA-1993-P-0037-0027,FDA,FDA-1993-P-0037,Points to Consider re: Petition for Stay,Other,Background Material,2010-05-27T04:00:00Z,2010,5,2010-05-27T04:00:00Z,,2025-09-19T20:23:46Z,,0,0,09000064804fbeaf
FDA-1993-P-0037-0026,FDA,FDA-1993-P-0037,"Tab F - Letter from Wiley, Rein & Fielding to FDA DMB re: Petition for Stay",Other,Background Material,2010-05-27T04:00:00Z,2010,5,2010-05-27T04:00:00Z,,2025-09-19T20:20:53Z,,0,0,09000064804fbeac
FDA-1993-P-0037-0025,FDA,FDA-1993-P-0037,"Tab E - Letter from Wiley, Rein & Fielding to FDA DMB re: Petition for Stay",Other,Background Material,2010-05-27T04:00:00Z,2010,5,2010-05-27T04:00:00Z,,2025-09-19T20:11:52Z,,0,0,09000064804fbea8
FDA-1993-P-0037-0029,FDA,FDA-1993-P-0037,Exhibit 5 - Biopharmaceutical Considerations re: Petition for Stay,Other,Background Material,2010-05-27T04:00:00Z,2010,5,2010-05-27T04:00:00Z,,2025-09-19T20:46:23Z,,0,0,09000064804fbeba
FDA-1993-P-0037-0028,FDA,FDA-1993-P-0037,"Petition for Withdrawal or Stay from Wiley, Rein & Fielding on behalf of Pfizer Inc.",Other,Petition(s),2010-05-27T04:00:00Z,2010,5,2010-05-27T04:00:00Z,,2025-09-19T20:25:34Z,,0,0,09000064804fbeb2
FDA-1993-P-0037-0023,FDA,FDA-1993-P-0037,"Tab 26 - Center for Drug Evaluation and Research, FDA, Tr. for Jan. 11-12, 1994 Meeting of the Generic Drug Advisory Committee",Other,Supplement (SUP),2010-05-21T04:00:00Z,2010,5,2010-05-21T04:00:00Z,,2025-09-19T20:01:24Z,,0,0,09000064804fbe44
FDA-1993-P-0037-0021,FDA,FDA-1993-P-0037,"Tab 26 - Center for Drug Evaluation and Research, FDA, Tr. for Jan. 11-12, 1994 Meeting of the Generic Drug Advisory Committee",Other,Supplement (SUP),2010-05-21T04:00:00Z,2010,5,2010-05-21T04:00:00Z,,2025-09-19T19:54:49Z,,0,0,09000064804fbe3a
FDA-1993-P-0037-0019,FDA,FDA-1993-P-0037,"Tab 25 - Center for Drug Evaluation and Research, FDA, Tr. for Jan. 11-12, 1994 Meeting of the Generic Drug Advisory Committee",Other,Supplement (SUP),2010-05-21T04:00:00Z,2010,5,2010-05-21T04:00:00Z,,2025-09-19T19:51:44Z,,0,0,09000064804fbe30
FDA-1993-P-0037-0022,FDA,FDA-1993-P-0037,"Tab 26 - Center for Drug Evaluation and Research, FDA, Tr. for Jan. 11-12, 1994 Meeting of the Generic Drug Advisory Committee",Other,Supplement (SUP),2010-05-21T04:00:00Z,2010,5,2010-05-21T04:00:00Z,,2025-09-19T20:00:12Z,,0,0,09000064804fbe3e
FDA-1993-P-0037-0020,FDA,FDA-1993-P-0037,"Tab 25 - Center for Drug Evaluation and Research, FDA, Tr. for Jan. 11-12, 1994 Meeting of the Generic Drug Advisory Committee",Other,Supplement (SUP),2010-05-21T04:00:00Z,2010,5,2010-05-21T04:00:00Z,,2025-09-19T19:53:01Z,,0,0,09000064804fbe35
FDA-1993-P-0037-0017,FDA,FDA-1993-P-0037,"Tab 24 - Center for Drug Evaluation and Research, FDA, Summary Minutes for Jan. 11-12, 1994 Meeting of the Generic Drug Advisory Committee (June 26, 1994)",Other,Supplement (SUP),2010-04-29T04:00:00Z,2010,4,2010-04-29T04:00:00Z,,2025-09-19T19:48:50Z,,0,0,09000064804fbe27
FDA-1993-P-0037-0016,FDA,FDA-1993-P-0037,Supplement 2 re: Pfizer Inc.,Other,Supplement (SUP),2010-04-29T04:00:00Z,2010,4,2010-04-29T04:00:00Z,,2025-09-19T19:42:51Z,,0,0,09000064804fbe22
FDA-1993-P-0037-0018,FDA,FDA-1993-P-0037,"Tab 25 - Center for Drug Evaluation and Research, FDA, Tr. for Jan. 11-12, 1994 Meeting of the Generic Drug Advisory Committee",Other,Supplement (SUP),2010-04-29T04:00:00Z,2010,4,2010-04-29T04:00:00Z,,2025-09-19T19:50:41Z,,0,0,09000064804fbe2a
FDA-1993-P-0037-0005,FDA,FDA-1993-P-0037,Supplement 1 re: Pfizer Inc.,Other,Supplement (SUP),2010-04-28T04:00:00Z,2010,4,2010-04-28T04:00:00Z,,2025-09-19T19:35:26Z,,0,0,09000064804fbdcc
FDA-1993-P-0037-0015,FDA,FDA-1993-P-0037,Supplement 2 re: Pfizer Inc.,Other,Supplement (SUP),2010-04-28T04:00:00Z,2010,4,2010-04-28T04:00:00Z,,2025-09-19T19:40:50Z,,0,0,09000064804fbe48
FDA-1993-P-0037-0013,FDA,FDA-1993-P-0037,Supplement 3 re: Pfizer Inc.,Other,Supplement (SUP),2010-04-28T04:00:00Z,2010,4,2010-04-28T04:00:00Z,,2025-09-19T19:33:17Z,,0,0,09000064804fbea2
FDA-1993-P-0037-0008,FDA,FDA-1993-P-0037,"Letter from FDA CDER to Wiley, Rein & Fielding",Other,Letter(s),2010-04-28T04:00:00Z,2010,4,2010-04-28T04:00:00Z,,2025-01-28T15:16:42Z,,0,0,09000064804fbddc
FDA-1993-P-0037-0003,FDA,FDA-1993-P-0037,"Citizen Petition from Wiley, Rein & Fielding on behalf of Pfizer Inc.",Other,Citizen Petition,2010-04-28T04:00:00Z,2010,4,2010-04-28T04:00:00Z,,2025-01-28T14:56:02Z,,0,0,09000064804fbda2
FDA-1993-P-0037-0004,FDA,FDA-1993-P-0037,Exhibit 3 -Approved Drug Products with Therapeutic Equivalence Evaluations,Other,Exhibit(s),2010-04-28T04:00:00Z,2010,4,2010-04-28T04:00:00Z,,2025-09-19T19:28:51Z,,0,0,09000064804fbdc0
FDA-1993-P-0037-0002,FDA,FDA-1993-P-0037,"Acknowledgement Letter from FDA DMB to Wiley, Rein & Fielding",Other,Acknowledgement Letter/Receipt,1997-07-02T04:00:00Z,1997,7,,,2025-01-28T14:48:40Z,,0,0,09000064804fbefb